Scohia Pharma Raises 3 Billion JPY via Third-Party Allotment

Scohia Pharma (Headquarters: Fujisawa, Kanagawa; Representative Director: Masanori Watanabe) announced that it has raised 3 billion JPY through a third-party allotment of shares. Established in 2017 as a carve-out from Takeda Pharmaceutical, the company is a drug discovery venture specializing in the endocrine, cardiovascular, renal, and metabolic fields. Its strengths lie in a research team with extensive experience and a development structure capable of handling everything from target discovery to clinical development. The company focuses on rare diseases with limited treatment options and the rapidly expanding obesity market, managing multiple programs in parallel to ensure continuous value creation and risk diversification. To date, the company has licensed out its proprietary compound SCO-483 to Neurocrine Biosciences, SCO-094 (clinical stage) to Huadong Medicine, and the rights to SCO-116 (preclinical stage) for ophthalmology and dermatology to Kuria Therapeutics. Additionally, in the obesity sector, it has entered a strategic collaboration with Celltrion, identifying the lead compound SCO-940. The funds raised will be used to further expand business, primarily for the following projects: SCO-240 (SSTR5 antagonist for growth hormone deficiency, Ph1 complete) and SCO-792 (enteropeptidase inhibitor for ADPKD, Ph1 complete), as well as advancing next-generation preclinical programs and creating new pipelines. The company aims to maximize pipeline value through flexible resource allocation and continue delivering innovative treatments to patients.